| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kuang-Wei Wang, Gary Zhang, Min-Hao Ku. Frontotemporal Dementia P301L Mutation Potentiates but Is Not Sufficient to Cause the Formation of Cytotoxic Fibrils of Tau. International journal of molecular sciences. vol 24. issue 19. 2023-10-14. PMID:37834443. |
understanding the conditions and mechanisms whereby selective mutations aggravate the pathogenic activities of tau can provide pivotal clues on novel strategies for drug development for frontotemporal dementia and other related neurodegenerative tauopathies, including alzheimer's disease. |
2023-10-14 |
2023-10-15 |
Not clear |
| Jiaxin Hu, Wenchi Sha, Shuangshuang Yuan, Jiarui Wu, Yunpeng Huan. Aggregation, Transmission, and Toxicity of the Microtubule-Associated Protein Tau: A Complex Comprehension. International journal of molecular sciences. vol 24. issue 19. 2023-10-14. PMID:37834471. |
tau protein aggregates can be found in a number of devastating neurodegenerative diseases known as "tauopathies", such as alzheimer's disease (ad), frontotemporal dementia (ftd), corticobasal degeneration (cbd), etc. |
2023-10-14 |
2023-10-15 |
Not clear |
| Benjamin C Creekmore, Ryohei Watanabe, Edward B Le. Neurodegenerative Disease Tauopathies. Annual review of pathology. 2023-10-13. PMID:37832941. |
tauopathies are a diverse group of progressive and fatal neurodegenerative diseases characterized by aberrant tau inclusions in the central nervous system. |
2023-10-13 |
2023-10-15 |
Not clear |
| Xiaohuan Sun, Victor C Ogbolu, Peter W Baas, Liang Qian. Reevaluating tau reduction as a therapeutic approach for tauopathies: Insights and perspectives. Cytoskeleton (Hoboken, N.J.). 2023-10-11. PMID:37819557. |
reevaluating tau reduction as a therapeutic approach for tauopathies: insights and perspectives. |
2023-10-11 |
2023-10-15 |
mouse |
| Xiaohuan Sun, Victor C Ogbolu, Peter W Baas, Liang Qian. Reevaluating tau reduction as a therapeutic approach for tauopathies: Insights and perspectives. Cytoskeleton (Hoboken, N.J.). 2023-10-11. PMID:37819557. |
while reducing tau levels shows therapeutic promise for early tauopathies, efficacy wanes in later stages due to resilient toxic tau aggregates and neurofibrillary tangles. |
2023-10-11 |
2023-10-15 |
mouse |
| Xiaohuan Sun, Victor C Ogbolu, Peter W Baas, Liang Qian. Reevaluating tau reduction as a therapeutic approach for tauopathies: Insights and perspectives. Cytoskeleton (Hoboken, N.J.). 2023-10-11. PMID:37819557. |
notably, tauopathies involve factors beyond toxic tau alone, necessitating a broader therapeutic approach. |
2023-10-11 |
2023-10-15 |
mouse |
| Xiaohuan Sun, Victor C Ogbolu, Peter W Baas, Liang Qian. Reevaluating tau reduction as a therapeutic approach for tauopathies: Insights and perspectives. Cytoskeleton (Hoboken, N.J.). 2023-10-11. PMID:37819557. |
overexpression of human tau in mouse models, although useful for answering some questions, may not accurately reflect disease mechanisms in patients with tauopathies. |
2023-10-11 |
2023-10-15 |
mouse |
| Alejandra Del Carmen Alonso, Abdeslem El Idrissi, Robert Candia, Viktoriya Morozova, Frida Esther Kleima. Tau: More than a microtubule-binding protein in neurons. Cytoskeleton (Hoboken, N.J.). 2023-10-11. PMID:37819542. |
tau self-assembly in particular has made an impact, leading to the hypothesis that a prion-like function of hyperphosphorylated tau is central to tauopathies. |
2023-10-11 |
2023-10-15 |
Not clear |
| Sagar Gaikwad, Sudipta Senapati, Md Anzarul Haque, Rakez Kaye. Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023-10-10. PMID:37814508. |
aging, tau pathology, and chronic inflammation in the brain play crucial roles in synaptic loss, neurodegeneration, and cognitive decline in tauopathies, including alzheimer's disease. |
2023-10-10 |
2023-10-15 |
Not clear |
| Sagar Gaikwad, Sudipta Senapati, Md Anzarul Haque, Rakez Kaye. Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023-10-10. PMID:37814508. |
highlights: senescence, oligomeric tau (tauo), and brain inflammation accelerate the aging process and promote the progression of tauopathies, including alzheimer's disease. |
2023-10-10 |
2023-10-15 |
Not clear |
| Kevin Llewelyn Batenburg, Susan Karijn Rohde, Paulien Cornelissen-Steijger, Nicole Breeuwsma, Vivi Majella Heine, Wiep Schepe. A Human Neuron/Astrocyte Co-culture to Model Seeded and Spontaneous Intraneuronal Tau Aggregation. Current protocols. vol 3. issue 10. 2023-10-06. PMID:37801344. |
how neuron/astrocyte crosstalk is affected by intraneuronal tau aggregation in neurodegenerative tauopathies is largely elusive. |
2023-10-06 |
2023-10-07 |
human |
| Joshua T Emmerson, Janice C Malcolm, Sonia Do Carmo, Phuoc Nguyen, Lionel Breuillaud, Julio C Martinez-Trujillo, A Claudio Cuell. Neuronal loss and inflammation preceding fibrillary tau pathology in a rat model with early human-like tauopathy. Neurobiology of disease. 2023-10-06. PMID:37802153. |
in tauopathies such as alzheimer's disease (ad) and frontotemporal dementia (ftd), the microtubule associated protein tau undergoes conformational and posttranslational modifications in a gradual, staged pathological process. |
2023-10-06 |
2023-10-15 |
human |
| Kimberly L Fiock, Jordan N Hook, Marco M Heft. Determinants of astrocytic pathology in stem cell models of primary tauopathies. Acta neuropathologica communications. vol 11. issue 1. 2023-10-06. PMID:37803326. |
astrocytic tau aggregates are seen in several primary and secondary tauopathies, including progressive supranuclear palsy (psp), corticobasal degeneration (cbd), and chronic traumatic encephalopathy (cte). |
2023-10-06 |
2023-10-15 |
human |
| Kimberly L Fiock, Jordan N Hook, Marco M Heft. Determinants of astrocytic pathology in stem cell models of primary tauopathies. Acta neuropathologica communications. vol 11. issue 1. 2023-10-06. PMID:37803326. |
we used a combination of rna in situ hybridization and immunofluorescence in post-mortem human brain tissue, as well as tau uptake studies in human stem cell-derived astrocytes, to determine the origins of astrocytic tau in 4r tauopathies. |
2023-10-06 |
2023-10-15 |
human |
| Jeffrey L Cummings, M Isabel Gonzalez, Martyn C Pritchard, Patrick C May, Leticia M Toledo-Sherman, Glenn A Harri. The therapeutic landscape of tauopathies: challenges and prospects. Alzheimer's research & therapy. vol 15. issue 1. 2023-10-06. PMID:37803386. |
tauopathies are a group of neurodegenerative disorders characterized by the aggregation of the microtubule-associated protein tau. |
2023-10-06 |
2023-10-15 |
Not clear |
| Hans Zempe. Genetic and sporadic forms of tauopathies-TAU as a disease driver for the majority of patients but the minority of tauopathies. Cytoskeleton (Hoboken, N.J.). 2023-10-05. PMID:37795931. |
we now include: (i) tauopathies where the disease cause or trigger is clearly either physical, such as in traumatic brain injury (tbi) or chronic traumatic encephalopathy (cte), and (ii) genetic diseases that result in tauopathy but have pathogenic genetic variants in genes not related to tau. |
2023-10-05 |
2023-10-07 |
Not clear |
| Hans Zempe. Genetic and sporadic forms of tauopathies-TAU as a disease driver for the majority of patients but the minority of tauopathies. Cytoskeleton (Hoboken, N.J.). 2023-10-05. PMID:37795931. |
improved understanding of rare tauopathies is necessary to develop specific treatments, but also to improve our understanding of the pathomechanistic role of tau and to identify diseases that may profit from tau-based therapies. |
2023-10-05 |
2023-10-07 |
Not clear |
| Manuel Schweighauser, Alexey G Murzin, Jennifer Macdonald, Isabelle Lavenir, R Anthony Crowther, Sjors H W Scheres, Michel Goeder. Cryo-EM structures of tau filaments from the brains of mice transgenic for human mutant P301S Tau. Acta neuropathologica communications. vol 11. issue 1. 2023-10-05. PMID:37798679. |
mice transgenic for human mutant p301s tau are widely used as models for human tauopathies. |
2023-10-05 |
2023-10-07 |
mouse |
| Michael O Isei, Peter A Girardi, Joel Rodwell-Bullock, Keith Nehrke, Gail V W Johnso. Site-specific phosphorylation of tau impacts mitochondrial function and response to stressors. Journal of neurochemistry. 2023-10-03. PMID:37787052. |
altogether, these findings show that phosphorylated tau increases mitochondrial susceptibility to stressors and extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including ad. |
2023-10-03 |
2023-10-07 |
mouse |
| Laura Vidal-Palencia, Cristina Font, Agustín Rebollada-Merino, Gabriel Santpere, Pol Andrés-Benito, Isidro Ferrer, Martí Pumarol. Primary Feline Tauopathy: Clinical, Morphological, Immunohistochemical, and Genetic Studies. Animals : an open access journal from MDPI. vol 13. issue 18. 2023-09-28. PMID:37760385. |
tauopathies are a group of neurodegenerative diseases characterized by the pathological aggregation of hyperphosphorylated tau in neurons and glia. |
2023-09-28 |
2023-10-07 |
cat |